Jitka Smetanova Tomas Milota Michal Rataj Jana Hurnakova Hana Zelena Rudolf Horvath
10.3389/fimmu.2022.1017232
Front Immunol
2022 Nov 9;13:1017232.
covid-19 sars-cov-2 fibrodysplasia ossificans progressive immunogenicity safety vaccination
CC BY
https://pubmed.ncbi.nlm.nih.gov/36439163/
COVID-19 Vaccines / administration & dosage COVID-19 / prevention & control Myositis Ossificans Vaccines
COVID-19 Vaccines / administration & dosage COVID-19 / prevention & control Myositis Ossificans Vaccines Research Support, Non-U.S. Gov't BNT162 Vaccine Humans Immunity, Cellular SARS-CoV-2 BNT162 Vaccine COVID-19 Vaccines Vaccines
PMC9682080
36439163
SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients
2022